Why is America running short of cancer drugs?
Problems at a manufacturing plant in India force doctors to ration care
Cancer is always a crisis. And lately, that crisis has been compounded by a shortage of two chemotherapy drugs, The New York Times reported. A shortfall of carboplatin and cisplatin is "forcing patients and their doctors to face even grimmer realities than those cancer typically presents." And there are few signs the shortage will end anytime soon. "Some companies that sell the medications are projecting that the shortage will last through the fall or later."
What's causing the shortage? The Washington Post reported the problem originated at a plant in India that was producing half of America's supply of cisplatin. It suspended production after a November inspection by the U.S. Food and Drug Administration turned up a "cascade of failure" in quality control. The pandemic revealed the fragility of the world's supply lines, and this is just the latest case. "A disruption at a single plant can trigger widespread shortages when other manufacturers can't make up the difference."
The shortage is "forcing thousands of patients to miss life-saving treatments," the Financial Times reported. Hospitals are delaying treatments in some cases and using substitute drugs in others. "Are we potentially in some way reducing the chance for cure?" asked Julie Gralow at the American Society of Clinical Oncology. "I don't think we have solid data on that, but that is a serious concern." Why is America facing a cancer drug shortage? And what can be done about it?
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
What are commentators saying?
"Cancer drugs are not scarce for the same reasons that yeast, toilet paper or couches were," Ed Yong wrote at The Atlantic. The problem isn't a pandemic or a ship stuck in a canal but because the overall market for generic pharmaceuticals is "utterly dysfunctional." Generic drugs are sold cheaply, but cancer drugs are hard to make, and doing so safely usually isn't cheap. The low margins on such drugs have pushed some manufacturers out of the market, leaving a few at-capacity factories to shoulder the load. When problems arise, then, they cascade quickly. "Any disruption to production has severe consequences."
The problem is rooted in America's overreliance on foreign suppliers, Tinglong Dai and Christopher S. Tang wrote for Barron's. "Either we take steps to phase out our reliance on foreign manufacturers, or the FDA needs to step up its quality inspections." Nearly 3,000 foreign factories provide most of America's pharmaceuticals, but the FDA inspected just 6% of them in 2022. That means crises like the cancer drug shortage are always lurking. "This is a glaring failure hidden in plain sight."
"Cancer drug shortages should have patients rioting in the streets," Kristen Rice, a San Diego oncologist, wrote for STAT News. There are no "silver bullet" solutions to the shortage, but it's clear that the economics of drug manufacturing are "broken." Policymakers should put "everything on the table," including tax breaks for generic drug makers and other measures to "boost manufacturer competition and strengthen supply chains." The effort will require buy-in from both the public and private sectors. "Cancer patients' lives depend on it."
What's next
Policymakers are looking for both short-term and long-term fixes. The New York Times reported that the FDA has responded to the shortage by allowing temporary imports of cisplatin from Qilo Pharmaceutical, a Chinese drug manufacturer, and that distribution of the drug started in early June. One Florida doctor said the new shipments are not enough to fully meet the need. "It's about six days of treatment for us," he said.
Congress is also looking to intervene. The Hill reported that a House health subcommittee held a hearing on the issue in mid-June. Recommendations included incentivizing new manufacturing technology and reforming the U.S. Strategic National Stockpile. "Today's shortages are the worst that I've seen in my 30-year career," Gralow told the committee.
Meanwhile, ABC News reported, Sens. Gary Peters (D-Mich.) and Joni Ernst (R-Iowa) have introduced legislation that would require federal agencies to assess vulnerabilities in the drug supply chain and offer proposed reforms. That, Peters said, should reduce how American "overreliance on foreign nations for critical drugs threatens our military readiness and creates health risks for Americans."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Joel Mathis is a writer with 30 years of newspaper and online journalism experience. His work also regularly appears in National Geographic and The Kansas City Star. His awards include best online commentary at the Online News Association and (twice) at the City and Regional Magazine Association.
-
Can Ukraine win over Donald Trump?
Today's Big Question Officials in Kyiv remain optimistic they can secure continued support from the US under a Trump presidency
By Richard Windsor, The Week UK Published
-
Orbital by Samantha Harvey: the Booker prize-winner set to go 'stratospheric'
In The Spotlight 'Bold' and 'scintillating' novel follows six astronauts orbiting Earth on the International Space Station over 24 hours
By Irenie Forshaw, The Week UK Published
-
Gladiator II: Paul Mescal 'mesmerising' in 'relentlessly entertaining' sequel
The Week Recommends Ridley Scott's 'primary aim' is fun, in this 'exhilarating' blockbuster
By Irenie Forshaw, The Week UK Published
-
The dark side of the contraceptive coil
Under the Radar Study linking hormonal IUD to increased breast cancer risk adds to growing concerns about whether the benefits of the coil outweigh the risks
By Harriet Marsden, The Week UK Published
-
Pink cocaine: the new drug cocktail responsible for an increasing number of deaths
In the Spotlight The substance has been linked to the death of Liam Payne and named in a lawsuit against Sean 'Diddy' Combs
By Justin Klawans, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Why scurvy is on the rise
The Explainer Cost of living and poor dietary choices fuelling a potential resurgence of condition associated with the Age of Sail
By Richard Windsor, The Week UK Published
-
What went wrong at CVS?
Today's Big Question Pharmacy chains are in crisis
By Joel Mathis, The Week US Published
-
The 'game-changing' treatment for schizophrenia
The Explainer US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects
By Harriet Marsden, The Week UK Published
-
The audio industry is working to tackle hearing aid stigma
The Explainer Only 1 in 5 people who could benefit from hearing aids use them, according to the Hearing Loss Association of America
By Justin Klawans, The Week US Published
-
Mold, bugs at listeria-linked Boar's Head meat plant
Speed Read Food safety inspectors reported many violations at a Virginia plant that has been linked to a nationwide deli meat recall
By Peter Weber, The Week US Published